» Articles » PMID: 38501170

Cross-species Modeling of Muscular Dystrophy in Caenorhabditis Elegans Using Patient-derived Extracellular Vesicles

Overview
Journal Dis Model Mech
Specialty General Medicine
Date 2024 Mar 19
PMID 38501170
Authors
Affiliations
Soon will be listed here.
Abstract

Reliable disease models are critical for medicine advancement. Here, we established a versatile human disease model system using patient-derived extracellular vesicles (EVs), which transfer a pathology-inducing cargo from a patient to a recipient naïve model organism. As a proof of principle, we applied EVs from the serum of patients with muscular dystrophy to Caenorhabditis elegans and demonstrated their capability to induce a spectrum of muscle pathologies, including lifespan shortening and robust impairment of muscle organization and function. This demonstrates that patient-derived EVs can deliver disease-relevant pathologies between species and can be exploited for establishing novel and personalized models of human disease. Such models can potentially be used for disease diagnosis, prognosis, analyzing treatment responses, drug screening and identification of the disease-transmitting cargo of patient-derived EVs and their cellular targets. This system complements traditional genetic disease models and enables modeling of multifactorial diseases and of those not yet associated with specific genetic mutations.

Citing Articles

Multiscale brain modeling: bridging microscopic and macroscopic brain dynamics for clinical and technological applications.

Krejcar O, Namazi H Front Cell Neurosci. 2025; 19:1537462.

PMID: 40046848 PMC: 11879965. DOI: 10.3389/fncel.2025.1537462.

References
1.
Blake D, Weir A, Newey S, Davies K . Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002; 82(2):291-329. DOI: 10.1152/physrev.00028.2001. View

2.
Apfeld J, Alper S . What Can We Learn About Human Disease from the Nematode C. elegans?. Methods Mol Biol. 2018; 1706:53-75. PMC: 6391162. DOI: 10.1007/978-1-4939-7471-9_4. View

3.
Bushby K, Goodship J, Nicholson L, Johnson M, Haggerty I, Gardner-Medwin D . Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 1993; 3(1):57-64. DOI: 10.1016/0960-8966(93)90042-i. View

4.
Huebner K, Jassal D, Halevy O, Pines M, Anderson J . Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am J Physiol Heart Circ Physiol. 2008; 294(4):H1550-61. DOI: 10.1152/ajpheart.01253.2007. View

5.
MacKenzie S, Nicolau S, Connolly A, Mendell J . Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New. Semin Pediatr Neurol. 2021; 37:100877. DOI: 10.1016/j.spen.2021.100877. View